Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men.

Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men. Abstract Text:

Kathryn E Ryan,D R McCance,L Powell,R McMahon,E R Trimble,Kathryn E Ryan,D R McCance,L Powell,R McMahon,E R Trimble,

Obesity is a low grade inflammatory state associated with premature cardiovascular morbidity and mortality. Along with traditional risk factors the measurement of endothelial function, insulin resistance, inflammation and arterial stiffness may contribute to the assessment of cardiovascular risk. We conducted a randomised placebo controlled trial to assess the effects of 12 weeks treatment with a PPAR alpha agonist (fenofibrate) and a PPAR gamma agonist (pioglitazone) on these parameters in obese glucose tolerant men. Arterial stiffness was measured using augmentation index and pulse wave velocity (PWV). E-selectin, VCAM-1 and ICAM-1 were used as markers of endothelial function. Insulin sensitivity improved with pioglitazone treatment (p=0.001) and, in keeping with this, adiponectin increased by 85.2% (p<0.001). Pro-inflammatory cytokine levels (TNFalpha, IL-6 and IL-1 beta) fell with both treatments (p<0.01 for TNFalpha and IL-1 beta, p<0.001 for IL-6). VCAM-1 and ICAM-1 were reduced with both treatments (p<0.001 for VCAM-1, p<0.05 for ICAM-1) and E-selectin improved with pioglitazone treatment (p=0.05). Both treatments resulted in a fall in augmentation index. PWV fell by 17.4% with fenofibrate treatment (p<0.001) and 16.3% with pioglitazone treatment (p<0.001). Pioglitazone and fenofibrate treatment of obese, glucose tolerant men reduces inflammation, improves markers of endothelial function and reduces arterial stiffness. These results suggest that treatment with PPAR agonists has potential to reduce the incidence of premature cardiovascular disease associated with obesity.

Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men. Publishing Authors By Initials

KE Ryan,DR McCance,L Powell,R McMahon,ER Trimble,KE Ryan,DR McCance,L Powell,R McMahon,ER Trimble,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Atherosclerosis

VOLUME: 194

Page Numbers: e123-30

Journal Abbreviation: Atherosclerosis

ISSN: 0021-9150

DAY: 4

MONTH: 12

YEAR: 2006

Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 242543

Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men.

AFFILIATION: The Royal Group of Hospitals, Belfast, UK.

Country: Ireland

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Atherosclerosis

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men Related Publications

• Are patients with somatization disorder highly suggestible?
• Behavioral correlates of posteromedial parietal cortex hypometabolism in a family with idiopathic basal ganglia calcifications.
• Body image and the temporal lobes.
• Comparison of efficacy of pheromone dispensing technologies for controlling the grape berry moth (Lepidoptera: Tortricidae) by mating disruption.
• Correspondence between self-ratings and key-workers' ratings of depression in adults with mild learning disabilities.
• Demographic, clinical, and treatment trends among women diagnosed with vulvar cancer in the United States.
• Embracing alternative perspectives.
• Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men.
• Funding patient-reported outcomes in cancer clinical trials.
• Harold Guyon Trimble; 1896-1957.
• Health-related quality of life and symptom management research sponsored by the National Cancer Institute.
• Infusion-aspiration control.
• Interictal psychoses of epilepsy.
• Mammalian SEPT2 is required for scaffolding nonmuscle myosin II and its kinases.
• Neurobiologic perspectives.
• Neurobiologic perspectives.
• Numbering fingers.
• Patient-reported outcomes assessment in cancer trials: taking stock, moving forward.
• Patterns of care for cervical cancer patients treated in the U.S. military health care system.
• Promotion of bicycle helmet use among schoolchildren: a randomized clinical trial.
• Sept12 is a component of the mammalian sperm tail annulus.
• The changing concept in pneumonia.
• The coblentz society newsletter.
• The contemporary relevance of neuropsychiatry.
• The dopaminergic projection system, Basal forebrain macrosystems, and conditioned stimuli.
• The lesson of encephalitis lethargica.
• The septin CDCrel-1 is dispensable for normal development and neurotransmitter release.
• The utilization of collapse therapy.
• The ventral striatum as an interface between the limbic and motor systems.
• Transcranial magnetic stimulation.